Chondroitin sulfates (CS), a class of glycosaminoglycans, are required for the formation of proteoglycans found in joint cartilage. It is believed they improve joint function by both enhancing endogenous synthesis and preventing enzymatic degradation of joint glycosaminoglycans. Evidence supports oral administration of chondroitin sulfates for degenerative joint disease, both as an agent to slowly reduce symptoms and to decrease the need for nonsteroidal anti-inflammatory drugs (NSAIDs). CS may also be of benefit in alleviating the symptoms of psoriasis. Animal studies suggest a potential healing benefit for inflammatory bowel disease and prevention of post-surgical adhesions.